Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability

This article was originally published in The Gray Sheet

Executive Summary

It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.
Advertisement

Related Content

FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions
Obesity Devices: Planned Risk-Tolerance Survey Could Impact CDRH Decision-Making
Risk And Benefit, Quantified: CDRH Expands Use Of New Statistical Framework
A Long, Strange Trip: 510(k) Reform At One Year
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
Shuren: New Clinical Trial Guidelines In The Works
Shuren: New Clinical Trial Guidelines In The Works
Innovation Efforts Offer A Way To Change FDA's Views On Risk, Industry Says

Topics

Advertisement
UsernamePublicRestriction

Register

MT030466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel